Oligodendrogliomas are primary brain tumors that tend to occur in young people and have poor prognosis. Developing deeper understanding of oligodendroglioma biology and creating new personalized therapies for this disease therefore a large unmet clinical need. Genome sequencing efforts have provided profound insights into genetic changes that characterize oligodendroglioma. Some of the genetic alterations commonly observed in adolescent and adult oligodendrogliomas are expected to have primary effects on cellular metabolism. Despite the likely role played by metabolic reprogramming in this disease, there have been few studies exploring this relationship. Researchers hypothesize that systematic metabolite profiling of oligodendroglioma samples will reveal metabolic hallmarks that help distinguish these gliomas from normal tissue and from other tumor types. Through this research it may be possible to discover unappreciated oligodendroglioma-specific metabolic dependencies that point to new therapeutic opportunities. The Children’s Brain Tumor Network will provide researchers with the rare oligodendroglioma samples necessary for this work. These associations may offer insights into the molecular origins and drivers of this disease.
What are the goals of this project?
Researchers are hoping to explore the effects that oligodendrogliomas have on cellular metabolism and map these key characteristics for this tumor type.
What is the impact of this project?
Personalized therapies for oligodendroglioma are greatly needed, this research may provide a novel therapeutic strategy.
Why is the CBTN request important to this project?
Oligodendrogliomas, especially those that arise in adolescents, are fairly rare brain tumors. As such, obtaining sufficient numbers of pediatric oligodendroglioma samples from sources other than the CBTN would be difficult and require years to collect in sufficient numbers if done prospectively. The samples requested from the CBTN are integral to our efforts to elucidate the biochemical landscape of oligodendroglioma and will uniquely accelerate our work in this area.
The Children’s Brain Tumor Network will provide researchers with rare oligodendroglioma samples that will allow researchers to carry out this line of investigation.
The Children's Brain Tumor Network will contribute to this project by providing tumor samples.
Samuel McBrayer, PhD
Our goal is to identify the metabolic mechanisms that push cells to become cancerous and find new ways to inhibit them. To identify these mechanisms, we study the biology of brain tumors driven by mutations in genes that regulate metabolism
Kalil Abdullah, MD
Dr. Abdullah directs an Integrated Brain Tumor Research Program that takes tumor tissue directly from the operating room to the laboratory to develop new drug and treatment targets. He is actively involved in both running and enrolling patients in clinical trials for brain tumors
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test
Low-Grade Gliomas also called astrocytomas are the most common cancer of the central nervous system in children. They represent a heterogeneous group of tumors that can be discovered anywhere within the brain or spinal cord. Although surgical resection may be curative, up to 20% of children still su
Oligodendroglioma is a primary central nervous system (CNS) tumor. This means it begins in the brain or spinal cord.Oligodendrogliomas are grouped in two grades based on their characteristics.Grade II oligodendrogliomas are low grade tumors. This means the tumor cells grow slowly and invade nearby n